United Therapeutics (UTHR) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of United Therapeutics (NASDAQ: UTHR) recently:

• 4/10/2026 – United Therapeutics had its price target raised by Morgan Stanley from $471.00 to $519.00. They now have an “equal weight” rating on the stock.
• 4/10/2026 – United Therapeutics is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $700.00 price target on the stock.
• 4/9/2026 – United Therapeutics is now covered by Raymond James Financial, Inc.. They set a “moderate buy” rating on the stock.
• 3/31/2026 – United Therapeutics had its price target raised by HC Wainwright from $600.00 to $660.00. They now have a “buy” rating on the stock.
• 3/31/2026 – United Therapeutics had its price target raised by Wells Fargo & Company from $486.00 to $575.00. They now have an “equal weight” rating on the stock.
• 3/31/2026 – United Therapeutics had its price target raised by Bank of America Corporation from $569.00 to $626.00. They now have a “neutral” rating on the stock.
• 3/30/2026 – United Therapeutics had its price target raised by TD Cowen from $575.00 to $660.00. They now have a “buy” rating on the stock.
• 3/23/2026 – United Therapeutics had its price target raised by Wells Fargo & Company from $466.00 to $486.00. They now have an “equal weight” rating on the stock.
• 3/12/2026 – United Therapeutics had its price target raised by Cantor Fitzgerald from $525.00 to $625.00. They now have an “overweight” rating on the stock.
• 3/5/2026 – United Therapeutics had its price target raised by UBS Group AG from $655.00 to $705.00. They now have a “buy” rating on the stock.
• 3/2/2026 – United Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 2/26/2026 – United Therapeutics had its price target raised by HC Wainwright from $525.00 to $600.00. They now have a “buy” rating on the stock.
• 2/26/2026 – United Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $575.00 to $600.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – United Therapeutics had its price target raised by Royal Bank Of Canada from $587.00 to $643.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – United Therapeutics had its price target raised by Wells Fargo & Company from $423.00 to $466.00. They now have an “equal weight” rating on the stock.
• 2/25/2026 – United Therapeutics had its price target raised by TD Cowen from $525.00 to $575.00. They now have a “buy” rating on the stock.
• 2/25/2026 – United Therapeutics had its “neutral” rating reaffirmed by Bank of America Corporation.
• 2/17/2026 – United Therapeutics had its “buy” rating reaffirmed by UBS Group AG.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 385,470 shares of company stock worth $200,956,248 in the last quarter. Insiders own 10.30% of the company’s stock.

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.